ZURA
Zura Bio Limited Class AstockNASDAQ
zura bio is a clinical-stage biotechnology company advancing zb-168 in alopecia areata and other inflammatory diseases. zb-168 is an anti il7rα inhibitor that has the potential to impact diseases driven by il7 and tslp biological pathways. zura bio aims to develop a portfolio of therapeutic indications for zb-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. this will build on phase 1b data in type 1 diabetes demonstrating a favourable safety profile and strong biological rationale. zura bio is headquartered in london, uk with team members in the uk and usa.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.24 | 2026-11-13 | -25.86% | -1.048 |
| 1M | 4.13 | 2026-10-21 | -77.74% | -1.844 |
| 3M | 5.85 | 2026-08-21 | -84.28% | -0.831 |
| 6M | 4.44 | 2026-05-21 | -79.30% | 0.086 |
| 1Y | 3.63 | 2025-11-21 | -74.67% | 0.624 |
| 2Y | 2.93 | 2024-11-21 | -68.63% | — |
| 5Y | 30.00 | 2023-03-22 | -96.94% | 1.285 |
Zura Bio Limited Class A (NASDAQ:ZURA) stock price today is $0.92, and today's volume is 4,773,859. ZURA is down 3.475% today. The 30 day average volume is 7.20M. ZURA market cap is $88.55M with 96.33M shares outstanding.